February 18-21, 2017
CRT 2017 is one of world’s leading interventional cardiology conferences and is being held in Washington, DC from February 18–21, 2017 at the Omni Shoreham Hotel. Stemming from a long history of success, this year’s CRT conference is destined to be the most cutting-edge and comprehensive interventional cardiology and structural heart interventional meeting ever.
Sharing ideas, collaborating on interventional cardiology solutions, receiving interventional cardiology training and networking with other professionals is only the tip of the iceberg of what’s happening at CRT 2017. The fact that this conference will provide focused educational and training sessions that discuss new trial data, explore evidence-based research, and demonstrate the most up-to-date techniques that can be directly applied to clinical and academic practices is always an exciting proposition for those who attend.
While remaining a boutique feel as an endovascular and interventional cardiology meeting, this interventional cardiology training event consists of four extremely impactful days of keynotes, presentations, workshops, a symposia, poster session, and discussions with thought leaders in interventional cardiology and structural cardiology. Special roundtable discussions about women and heart disease and women in interventional cardiology will also be featured at CRT 2017 along with much, much more.
Associates of Keystone Heart Ltd. are extremely excited to be attending this highly anticipated and elite event and further look forward to continuing their aspirations to be the world leader in cerebral embolic protection for cardiovascular procedures.
Presentations to Take Note of at CRT
Monday, February 20th
TAVR & PMVR: State of the Fields and discussion on TriGuard™ Case
Moderators: Maurice Buchbinder, MD, FSCAI, Michael J. Reardon, MD, and Samir R. Kapadia, MD, FSCAI
Cerebral Embolic Protection Devices
Moderators: Eberhard Grube, MD, FSCAI, Axel Linke, MD, Samir R. Kapadia, MD, FSCAI
Protection Devices for Stroke Prevention: Does the Data Support Routine Use?
Presenter: Eberhard Grube, MD, FSCAI
Update on SENTINEL Trial Technology and Clinical Outcome
Presenter: Samir R. Kapadia, MD, FSCAI
Technology Overview and Perspectives From the DEFLECT III Randomized Trial
Presenter: Alexandra J. Lansky, MD, FSCAI
Magnitude of Stroke Post-TAVR: Do We Need Cerebral Embolic Protection Devices?
Presenter: Michael J. Mack, MD
What Are the Options for Intervention of a Patient Who Has a Stroke After TAVR?
Presenter: Leo Nelson Hopkins, MD
Panel Discussion: Who Should Be a Candidate for Cerebral Embolic Protection Devices?
Moderators: Samir R. Kapadia, MD, FSCAI, Axel Linke, MD, Alexandra J. Lansky, MD, FSCAI
Panel: Michael Dwyer, PhD, Eberhard Grube, MD, FSCAI, Michael J. Mack, MD Rajendra Makkar, MD, FSCAI, Bruce J. Rutkin, MD
Tuesday, February 21st
The Keystone Deflector Device: Design Features and Clinical Trial Program
About Keystone Heart
Keystone Heart Ltd. is a medical device company developing and manufacturing cerebral protection devices. The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation and other cardiovascular procedures.
Headquartered in Israel with US operations in Tampa, FL, Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research. The Company’s management has extensive experience in the fields of interventional cardiology and medical devices.